NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 230 filers reported holding NOVOCURE LTD in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $742,850 | -33.2% | 17,900 | -3.2% | 0.01% | -37.5% |
| Q1 2023 | $1,112,590 | -17.6% | 18,500 | +0.5% | 0.02% | -23.8% |
| Q4 2022 | $1,349,640 | -3.5% | 18,400 | 0.0% | 0.02% | -8.7% |
| Q3 2022 | $1,398,000 | +9.9% | 18,400 | +0.5% | 0.02% | +15.0% |
| Q2 2022 | $1,272,000 | -16.1% | 18,300 | 0.0% | 0.02% | 0.0% |
| Q1 2022 | $1,516,000 | +8.6% | 18,300 | -1.6% | 0.02% | +17.6% |
| Q4 2021 | $1,396,000 | -35.0% | 18,600 | +0.5% | 0.02% | -41.4% |
| Q3 2021 | $2,149,000 | -50.1% | 18,500 | -4.6% | 0.03% | -47.3% |
| Q2 2021 | $4,304,000 | +68.7% | 19,400 | +0.5% | 0.06% | +52.8% |
| Q1 2021 | $2,551,000 | -26.7% | 19,300 | -4.0% | 0.04% | -26.5% |
| Q4 2020 | $3,478,000 | +63.6% | 20,100 | +5.2% | 0.05% | +40.0% |
| Q3 2020 | $2,126,000 | +89.7% | 19,100 | +1.1% | 0.04% | +66.7% |
| Q2 2020 | $1,121,000 | +29.0% | 18,900 | +46.5% | 0.02% | +10.5% |
| Q1 2020 | $869,000 | – | 12,900 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $27,923,000 | 10.09% |
| Darsana Capital Partners LP | 1,700,000 | $100,810,000 | 5.98% |
| HARTLINE INVESTMENT CORP/ | 336,617 | $19,961,000 | 4.18% |
| Rhenman & Partners Asset Management AB | 375,000 | $22,238,000 | 2.40% |
| MORGAN JESS S & CO INC | 35,942 | $2,131,000 | 2.31% |
| Soleus Capital Management, L.P. | 56,397 | $3,344,000 | 1.91% |
| Bullseye Asset Management LLC | 45,161 | $2,678,000 | 1.43% |
| Taylor Frigon Capital Management LLC | 46,304 | $2,746,000 | 1.36% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $593,000 | 1.09% |
| Redwood Investments, LLC | 192,986 | $11,444,000 | 1.01% |